Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Embarking on the quest to lose weight can be a risky business. Yo-yo dieting, compulsive binging, muscle wasting and brain ...

Obesity programs: <li /> Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ...

Zepbound is a brand name for a drug based on tirzepatide, a drug that includes both a GLP-1 agonist and a "gastric inhibitory polypeptide agonist." A GIP agonist promotes weight loss by affecting ...

As of Jan. 1, individual ACA plans and small-group plans from employers in the state include coverage for GLP-1s and gastric inhibitory polypeptide drugs, according to the North Dakota Insurance ...

August 15, 2024, Paper: "Glucagon-like peptide 1 (GLP-1) receptor agonists and dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists are among the most promising medical innovations of the ...

They act by targeting the incretin hormones-glucagon like peptide1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide/Gastric inhibitory polypeptide receptor (GIP-R). It is ...